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ABSTRACT 
Objective: A new, simple, rapid, accurate and economical method have been developed for the simultaneous estimation of Metformin HCl and  
Repaglinide in formulation.  
Method: The absorbances of both the drugs were determined at 238 nm and at 294 nm. The linearity was observed in the concentration range 
of 2-100 µg/ml and 1-35 µg/ml for Metformin HCl and Repaglinide respectively. The method was validated as per ICH guidelines.   
Result: The recovery of Metformin and Repaglinide was found in the range of 98.24 ± 0.325 to 100.25 ± 0.756.  
Conclusion: The proposed method was accurate, reproducible and economical and can be used successfully for quantitative estimation of 
Metformin HCl and Repaglinide in bulk and tablet dosage form. 
Keyword:- Metformin, Repaglinide, UV- spectrophotometric method, simultaneous estimation 
 
Article Info: Received 30 March 2019;     Review Completed 06 May 2019;     Accepted 10 May 2019;     Available online 15 May 2019 
Cite this article as: 
Kharbade S, Asnani A, Pratyush K, Development and Validation of UV Spectrophotometric Method for Simultaneous 
Estimation of Metformin HCl and Repaglinide in Pharmaceutical Formulation, Journal of Drug Delivery and Therapeutics. 
2019; 9(3):344-347   http://dx.doi.org/10.22270/jddt.v9i3.2676                                 
*Address for Correspondence:  
Sukanya Kharbade, Priyadarshini J. L. College of Pharmacy, Electronic Building, Electronic Zone, Hingna Road, Nagpur-440016 
 
1. INTRODUCTION 
Diabetes mellitus a chronic diseases across the world is a 
key disease for the exploring the therapeutic value of the 
drug [1]. The combined use of metformin and Repaglinide for 
type 2 diabetes mellitus was shown improved patient 
compliance by controlling the post prandial glucose levels 
and reaches normal glycemic levels.  Metformin 
Hydrochloride (MET) (Figure 1) is a biguanide class of 
antidiabetic drug; chemically is N, N-dimethylimido 
dicarbonimidicdiamide hydrochloride. It is an oralanti- 
antidiabetic drug from the biguanide class.[2-3] It is the first-
line drug for the treatment of type 2 diabetes, particularly in 
overweight and obese people and those with normal kidney 
function and evidence suggests it may be the best choice for 
people with heart failure. It is also used in the treatment of 
polycystic ovary syndrome. [4-9] Repaglinide (REPA) is the 
(Figure 1) Hypoglycaemic agents; Meglitinides, chemically it 
is (S)-2-Ethoxy-4-[2-[[methyl-1-[2-(1-piperidinyl)-phenyl] 
butyl] amino]-2-oxoethyl]-benzoic acid. For treatment of 
diabetes combinations with other hypoglycemic agents are 
commonly prescribed [10] In that 47.05% are two drug 
combination compares to single drug treatment (14.11%). 
There are various UV methods are available for estimation of 
this two drugs either individually  or in combination with 
other drug  and for both drug in combination two UV 
methods are available. Present work describes rapid, simple, 
sensitive, accurate and reproducible spectrophotometric 
methods [11] 
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Fig 1- Chemical structure of Metformin and Repaglinide 
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2. EXPERIMENTAL 
 MATERIAL AND METHODS 
 UV spectrophotometric method was carried out using 
Shimadzu 1800 double beam UV ‐ Visible spectrophoto-
meter with UV probe 2.33 software with a synchronized pair 
of 100 mm quartz cells were used for experimental reason. 
Preparation of standard stock solution 
An accurately weighed standard powder of 10 mg of MET 
and 10 mg of REPA were transferred in 10 ml volumetric 
flask separately, dissolved and diluted up to the mark with 
methanol AR grade, to get concentration 100 μg/ml of MET 
and 100 μg/ml of REPA. This solutions was used as a 
working standard solution (WSS). The working standard 
solution was further diluted by methanol to get require 
concentration of MET and REPA. 
The standard solution of MET and REPA were scanned in the 
range of 200-400nm against methanol as blank. Maximum 
absorbance was obtained at 238 nm and 294 nm MET and 
REPA respectively. 
Preparation of calibration curve 
The standard solution of MET were diluted with methanol to 
get series of standard solution having concentrations 2, 5, 
10, 20, 30, 40, 50,100 and REPA were diluted to get 
concentrations 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35 µg/ml. The 
absorbance of each solution was then measured at 238nm 
and 294 nm. 
Calibration curves were prepared by plotting the absorbance 
versus concentration of drug. The concentration of the 
unknown was read from the respective calibration curve or 
computed from the regression equation derived using the 
Beer’s law. 
Determination of E(1%1cm) of individual drug at 
selected wavelength 
Absorbance of individual drug was divided by concentration 
in g/100 ml to get the absorptivity coefficients of these drug 
which were determined at selected wavelength 
           A(1%, 1cm)= Absorbance/Concentration (g/ml) 
Table 1- A( 1%1 cm) of MET and REPA 
Drugs              Absorptivity of Drugs 
238 nm 294 nm 
MET 184.4 4.28 
REPA 204.8 70.4 
 
Simultaneous Equation Method 
Simultaneous equations were formed using these 
absorptivity coefficients values as follows. Quantitative 
estimation of MET and REPA were carried out by solving 
following simultaneous equations   
                     CX=A2×0.01691-A1×0.00581 
                    CY=A1×0.000353-A2×0.01523 
 Method Validation 
Linearity & Range: 
The linearity of proposed methods were evaluated by linear 
regression analysis, which was calculated by least square 
method. Calibration standards were prepared by spiking 
required volume of working standard solution100 μg/ml of 
MET and 10μg/ml of REPA into different 10ml volumetric 
flasks and volume made methanol to yield concentrations of 
2, 5 10, 20, 30, 40, 50 and 100μg/ml of MET and 1, 2, 3, 4, 5, 
10, 15, 20, 25, 30, and 35 μg/ml for REPA. Absorbance of the 
drugs was measured.  
Accuracy: 
Accuracy of the methods was determined at three different 
concentration levels i.e.80%, 100% and 120% in triplicate 
for each drug as per ICH guidelines.  
Precision: 
Precision was studied to find out intra and inter-day 
variations in the test method of MET and REPA. In this spike 
method is used in which pure drug is added. Intra‐day 
precision was determined by analyzing three concentration 
in three replicate measurements of within linearity range of 
drugs on three different times in the same day. Inter‐day 
precision was conducted during routine operation of the 
system over a period of 3 consecutive days.  
Limit of detection (LOD) and Limit of quantification 
(LOQ): 
LOD is the lowest amount of analyte in a sample that can be 
detected but not necessarily quantify under the stated 
experimental conditions. LOQ is the lowest concentration of 
analyte in a sample that can be determined with the 
acceptable precision and accuracy under stated 
experimental conditions 
The LOD and LOQ for MET and REPA were determined 
according to ICH guideline 
          LOD = 3.3σ                             
                        S 
          LOQ = 10σ 
                        S 
Where, σ = Standard deviation of the y intercept of 
calibration curves  
             S = Slope of the calibration curve 
RESULTS AND DISCUSSION 
Spectral characteristics 
By appropriate dilution of standard stock solution, solution 
containing 10 μg/ml of MET and 10 μg/ml of REPA was 
prepared in methanol. These diluted solutions were scanned 
in range 200-400 nm separately. Maximum absorbance was 
obtained 238 nm and 294 nm for MET and REPA, 
respectively. 
 
Fig 2- UV absorption overlay spectra of MET and REPA in 
methanol 
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Method validation 
Linearity Calibration plot was linear over2, 5, 10, 20, 30, 40, 
50,100 μg/ml for MET and 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35 
µg/ml for REPA 
 
Fig 3a- Calibration of Metformin 
 
Fig 3b-Calibration of Repaglinide 
Accuracy 
Accuracy of the methods was determined at three different 
concentration levels i.e.80%, 100% and 120% in triplicate 
for each drug as per ICH guidelines. From the total amount 
of drug found, the percentage recovery was fond in range of 
98.24 ± 0.325 to 100.25 ± 0.756.  
 
Table 2- Accuracy of MET and REPA 
Sr. No Amount of pure drug added 
(µg/ml) 
Amount of drug recovered 
(µg/ml) 
% Drug recovered 
80% recovery 
 MET REPA MET REPA MET REPA 
1 40 4 39.85 4.02 99.6 100.5 
2 40 4 40.02 3.96 100.06 99.09 
3 40 4 39.67 3.97 99.17 99.25 
100% recovery 
 MET REPA MET REPA MET  REPA 
1 50 5 49.95 5.01 99.9 100.04 
2 50 5 49.89 5.05 99.78 101.8 
3 50 5 50.50 5.05 101.05 101.8 
120%  recovery 
 MET REPA MET REPA MET REPA 
1 60 6 59.14 5.91 98.56 98.5 
2 60 6 58.95 5.90 98.25 98.33 
3 60 6 58.75 5.93 97.91 98.83 
 
Statistics 
Drug  Mean  ±SD RSD 
80% Recovery 
MET 99.61 0.445 0.446 
REPA 99.61 0.772 0.775 
100% Recovery 
MET 100.24 0.701 0.7003 
REPA 100.25 0.756 0.758 
120% Recovery 
MET 98.24 0.325 0.330 
REPA 98.55 0.254 0.257 
 
Precision: 
Precision was studied to find out intra and inter-day 
variations in the test method of MET and REPA. Intra‐day 
precision was determined by analyzing three concentration 
in three replicate measurements of within linearity range of 
drugs on three different times in the same day. Inter‐day 
precision was conducted during routine operation of the 
system over a period of 3 consecutive days. The precision of 
an analytical method is expressed as %RSD of a series of 
measurements which should be less than 2 %. 
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Table 3 – Intraday study of MET and REPA 
Time  Amount of tablet 
powder taken (g) 
Amount of drug estimated 
(g/tablet) 
% drug estimated 
MET     REPA MET     REPA 
0 hrs 0.6424 0.4986 0.05010 99.78 100.02 
3 hrs 0.6423 0.5005 0.04981 100.10 99.61 
6 hrs 0.6426 0.4974 0.04975 99.44 99.45 
 
Statistics  
Drugs  Mean  ±SD R.S.D 
MET 99.77 0.382 0.382 
REPA 99.75 0.428 0.429 
 
Table 4- Interday study of MET and REPA 
Days  Amount of tablet 
powder taken (g) 
Amount of drug estimated 
(g/tablet) 
% drug estimated 
MET     REPA MET     REPA 
Day 1 0.6425 0.5005 0.0496 100.1 99.21 
Day 2 0.6426 0.4991 0.0499 99.80 99.83 
Day 3 0.6424 0.4985 0.0497 99.65 99.45 
 
Statistics 
Drugs  Mean  ±SD R.S.D 
MET 99.83 0.199 0.200 
REPA 99.49 0.255 0.256 
 
Table 11. LOD and LOQ of MET and REPA 
Sr. No Drug LOD (μg/ml) LOQ (μg/ml) 
1. MET 0.0203 0.0617 
2. REPA 0.0169 0.0512 
 
CONCLUSION 
The developed method was accurate, precise and 
reproducible. The statistical parameters showed good 
results. The method was found to be simple, economical and 
time saving. This method can be successfully applied for 
routine quantitative estimation of metformin hydrochloride 
and repaglinide in bulk and solid dosage form.  
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